Cairn Diagnostics announced the launch of 13C-Spirulina Gastric Emptying Breath Test (GEBT) for measuring the rate of solid-phase gastric emptying and as an aid in the diagnosis of gastroparesis in symptomatic adults. It was initially approved by the Food and Drug Administration (FDA) in April 2015.

The non-radioactive and non-invasive GEBT allows for rapid and accurate diagnosis of gastroparesis. It can be administered at the physician’s office, a lab collection center, or in a tertiary care setting. 

RELATED: New Breath Test for Gastroparesis Approved by the FDA

The GEBT kit contains the specially labeled test meal and all necessary parts to administer the test meal and collect breath samples. It measures the rate of excretion of a special form of carbon dioxide in the patient’s breath. The test meal is a special egg mixture that contains pharmaceutical-grade Spirulina platensisi,  a blue green algae enriched with carbon-13. Consuming the 13C-enriched test meal raises 13CO2 and its rate of excretion at any time point is proportional to the rate of gastric emptying. 

The collected samples are returned to Cairn’s CLIA-certified clinical lab for analysis via gas isotope ratio mass spectometry (GIRMS). Test results are presented as a gastric emptying profile report and sent to the ordering clinician. 

For more information call (615) 376-5464 or visit